Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
The present invention provides for novel chimeric Ad-vectors carrying transgene, or portions of transgenes for stable and efficient gene transfer into diverse cell types or tissues in a CAR- and/or α υ β 3/5 -independent manner. Also provided are methods for producing such vectors and the use thereof for gene therapy to target a specific cell type or tissue.
1. A recombinant, double-stranded, adenovirus vector, wherein the vector comprises:
a. an adenovirus left inverted terminal repeat sequence;
b. an adenovirus packaging sequence;
c. a first adenoviral-associated inverted terminal repeat sequence;
d. a first inverted repeat sequence;
e. a heterologous promoter sequence which mediates transcription in a direction towards the adenoviral left inverted terminal repeat sequence in part a;
f. a foreign gene sequence;
g. a second inverted repeat sequence;
h. a second adenoviral-associated inverted terminal repeat sequence;
i. a gene sequence that mediates replication of an adenovirus in a transduced cell; and
j. an adenovirus right inverted terminal repeat sequence;
wherein the adenovirus packaging sequence is located on the one strand of the double-stranded vector; and wherein the other of the two strands of the double-stranded vector comprises a nucleotide sequence encoding a modified adenoviral fiber protein which alters the tropism of the adenovirus vector, and
wherein the modified adenoviral fiber protein is a modified fiber knob, a modified fiber tail or a modified fiber shaft.
2. A recombinant, double-stranded, adenovirus vector wherein the vector comprises:
a. an adenovirus left inverted terminal repeat sequence;
b. an adenovirus packaging sequence;
c. a first adenoviral-associated inverted terminal repeat sequence;
d. a first inverted repeat sequence;
e. a heterologous promoter sequence which mediates transcription in a direction away from the adenoviral left inverted terminal repeat sequence in part a;
f. a foreign gene sequence;
g. a second inverted repeat sequence;
h. a second adenoviral-associated inverted terminal repeat sequence;
i. a gene sequence that mediates replication of an adenovirus in a transduced cell; and
j. an adenovirus right inverted terminal repeat sequence;
wherein the adenovirus packaging sequence is located on one strand of the double-stranded vector of the vector; and wherein the other of the two strands of the double-stranded vector comprises a nucleotide sequence encoding a modified adenoviral fiber protein which alters the tropism of the adenovirus vector, and wherein the modified adenoviral fiber protein is a modified fiber knob, a modified fiber tail or a modified fiber shaft.
3. The adenoviral vector of claim 1 or 2 , wherein the modified fiber knob, the modified fiber tail or the modified fiber shaft is from an adenoviral serotype that differs from the serotype of the left or right adenoviral inverted terminal repeat sequence.
4. The adenoviral vector of claim 1 or 2 , wherein the modified fiber knob, the modified fiber tail or the modified fiber shaft is from adenoviral serotypes Ad3, Ad7, Ad9, Ad11 or Ad35.
5. The adenoviral vector of claim 1 or 2 , wherein the modified fiber knob binds a cell surface protein on a target cell of interest.
6. The adenoviral vector of claim 1 or 2 , wherein the modified fiber knob is modified in the G-H loop region or H-I loop region.
7. The adenoviral vector of claim 1 or 2 , wherein the modified fiber knob comprises a heterologous peptide ligand which replaces the G-H loop region or H-I loop region.
8. The adenoviral vector of claim 7 , wherein the heterologous peptide ligand is an RI or RII protein from malaria circumsporozoite surface protein (CS).
9. The adenoviral vector of claim 8 , wherein the RI protein from malaria circumsporozoite surface protein (CS) comprises the amino acid sequence KLKQPG (SEQ ID NO.:12).
10. The adenoviral vector of claim 8 , wherein the RII protein from malaria circumsporozoite surface protein (CS) comprises the amino acid sequence EWSPCSVTCGNGIQVRIK (SEQ ID NO.:13).
11. The adenoviral vector of claim 7 , wherein the heterologous peptide ligand comprises the amino acid sequence:
a. LGGKPDQ (SEQ ID NO.:15);
b. LNGCGSC (SEQ ID NO.:16);
c. LNGCGSGC (SEQ ID NO.:17); or
d. LNGCGXXXXXXXXXXGC (SEQ ID NO.:18).
12. The adenoviral vector of claim 1 or 2 which infects hepatocytes, bone marrow cells, stem cells or breast cancer cells.
13. The adenoviral vector of claim 1 or 2 , wherein the modified fiber shaft has a shortened length.
14. The adenoviral vector of claim 1 or 2 , wherein the adenoviral packaging sequence and the left and right adenoviral inverted terminal repeat sequences are from the same adenoviral serotype.
15. The adenoviral vector of claim 1 or 2 , wherein the adenoviral packaging sequence and the left and right adenoviral inverted repeat sequences are from serotype Ad5.
16. The adenoviral vector of claim 1 or 2 , wherein the foreign gene sequence encodes a therapeutic gene product, a selectable gene product, or a reporter gene product.
17. The adenoviral vector of claim 1 or 2 , wherein the therapeutic gene product is gamma globin or human alpha-1 antitrypsin.
18. The adenoviral vector of claim 1 or 2 , wherein the selectable gene product is neomycin, ampicillin, penicillin, tetracycline or gentamycin.
19. The adenoviral vector of claim 1 or 2 , wherein the reporter gene product is green fluorescent protein, beta galactosidase or alkaline phosphatase.
20. The adenoviral vector of claim 1 or 2 , further comprising an insulator element sequence.
21. The adenoviral vector of claim 1 or 2 , further comprising a bacterial origin of replication.
22. The adenoviral vector of claim 1 or 2 , further comprising a nucleotide sequence encoding a rep78 protein.
23. The adenoviral vector of claim 1 or 2 , wherein the gene sequence that mediates replication of an adenovirus in the transduced cell is selected from a group consisting of E2 and E4; E1, E2 and E4; and E2, E3 and E4.
24. The adenoviral vector of claim 1 or 2 , wherein the foreign gene sequence comprises a 5′ portion of the foreign gene sequence.
25. The adenoviral vector of claim 1 or 2 , wherein the foreign gene sequence comprises a 3′ portion of the foreign gene sequence.